Top Banner
Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center [email protected]
30

Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Mar 28, 2018

Download

Documents

doanlien
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Prognostic Factors for PTCL

Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

[email protected]

Page 2: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

International T-Cell Lymphoma Project

Distribution of 1314 Cases by Consensus Diagnosis

Vose J, et al. J Clin Oncol. 2008;26(25):4124-4130.

Page 3: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Overall Survival of PTCL

Vose J, et al. J Clin Oncol. 2008;26(25):4124-4130.

1314 cases From 22 centers worldwide All reviewed by a panel of experts Treated between 1990 and 2002

Page 4: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

p=0.80

International T-cell Lymphoma Project Overall Survival AITL vs PTCL-NOS

Prop

ortio

n

0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

Time 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

PTCL-U AILT

5 year OS ∼30%

Page 5: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

OS

(%)

Time (yrs)

IPI Censored Failed Total Median 0/1 36 47 83 5.03 2 36 67 103 2.1 3 20 53 73 1.41

4/5 9 38 47 0.68

P < .001

0 10 20 30 40 50 60 70 80 90

100

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Weisenburger DD, et al. Blood. 2011;117:3402-3408.

PTCL-NOS: OS by IPI

Page 6: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Overall Survival Based on Prognostic Score

Savage KJ, et al. Ann Oncol. 2004;15:1467-1475.

Prognostic Index for PTCL-U (N = 322)

0

20

40

60

80

100

0 12 24 36 48 60 72 84 96 Months

OS

(%)

Group 1 (0 adverse factors)

Group 2 (1 factor)

Group 3 (2 factors)

Group 4 (3-4 factors)

Gallamini A, et al. Blood. 2004;103:2474-2479.

PTCL-U by IPI

0

20

40

60

80

100

0 2 4 6 8 10 12 14 16 Years

OS

(%)

P < .00001 IPI 4/5 (n = 27)

IPI 2/3 (n = 54)

IPI 0/1 (n = 36)

Page 7: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Categories of Prognostic Factors

• Clinical Characteristics – Age, stage, ENS, PS, BM+ (IPI, PIT)

•  Laboratory Tests – LDH, monocytosis, B2M

• Histology of PTCL – Subtypes of T-cell NHL

• Genomics of PTCL – new models

Page 8: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Biologic Prognostic Markers in PTCL

Prognostic Marker Outcome EBV + Unfavorable Ki-67% > 80 Unfavorable Cytotoxic granule expression

Unfavorable

T-helper receptor profile – CCR3 or CCR5

Favorable

% transformed cells > 70%

Unfavorable

Proliferative signature Unfavorable NFkB signature Favorable

Page 9: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Prognostic Indices for T-cell NHL

•  International Prognostic Index (IPI) •  Prognostic Index for T-cell lymphoma

(PIT) – uses BM+ • Modified PIT (mPIT) – BM+ changed to

Ki-67 % •  International peripheral T-cell lymphoma

Project (IPTCLP) – based on PTCL and AITL only

Page 10: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Variables Used in Prognostic Indices for PTCL

Variable IPI PIT IPTCLP mPIT

Age > 60 X X X X

ECOG >1 X X X X

LDH > N X X X

Stage I/II vs. III/IV

X

ENS > 1 X

BM + X

Plt < 150 X

Ki-67 > 75% X

Page 11: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Overall survival of the patients with peripheral T-cell lymphoma (anaplastic large-cell lymphoma, ALK+ excluded) according to the different scores: (A) International Prognostic

Index (IPI), P < 0.0001; (B) International peripheral T-cell lymphoma Project score (IPTCLP), P < 0.0001; (C) PIT, P < 0.0001 and (D) modified Prognostic Index for T-cell lymphoma (mPIT), P

= 0.005.

G. Gutiérrez-García et al. Ann Oncol 2011;22:397-404

Page 12: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

0

200

400

600

800

1000

PTCL, Total PTCL-NOS ALCL ATLL AITL ENKTL

Year

Figure 1: Incidence rates by year, age-adjusted to the 2000 US population, expressed per 100,000 population (A); and proportion of PTCL cases by histologic subtype (B). PTCL, peripheral T-cell lymphoma; PTCL-NOS, PTCL not otherwise specified; ALCL, anaplastic large cell lymphoma; ATLL, adult T-cell leukemia/lymphoma; AITL, angioimmunoblastic T-cell lymphoma; ENKTL, extrandoal NK/T-cell lymphoma, nasal type. (N= 8802 in SEER 2000-2010)

Inci

denc

e, a

ge-a

djus

ted

per 1

00,0

00

PTCL-NOS ALCL AITL ATLL ENKTL T-PLL T-LGL SCPTCL EATL HSTL

12.7% 38.1%

24.2%

9.3%

6.9%

3.2 2.5 1.2

1.1 0.6

Petrich, et al: BJH 168: 708-718, 2015

Page 13: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Multivariate analysis of Survival •  Age > 55 years – 1 point •  African American Race – 1 point • Histology

• HSTL, EATL, ENKTL, T-PLL – 2 points

•  PTCL-NOS, AITL, ATLL, ALCL – 1 point

•  SCPTL, T-LGL – 0 points •  Advanced stage – 1 point

Petrich, et al: BJH 168: 708-718, 2015

Page 14: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Factors predicting survival in peripheral T‐cell lymphoma in the USA: a population‐based analysis of 8802 patients in the modern era

Petrich, et al: BJH 168: 708-718, 2015

Page 15: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Factors predicting survival in peripheral T‐cell lymphoma in the USA: a population‐based analysis of 8802 patients in the modern era

Petrich, et al: BJH 168: 708-718, 2015

Page 16: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Factors predicting survival in peripheral T‐cell lymphoma in the USA: a population‐based analysis of 8802 patients in the modern era

Petrich, et al: BJH 168: 708-718, 2015

Page 17: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Survival according to the new prognostic index. For NKT-cell – nasal type

Jeeyun Lee et al. JCO 2006;24:612-618

©2006 by American Society of Clinical Oncology

1.  B symptoms 2.  Stage > III 3.  LDH > normal 4.  LN N1-N3, not

M1

Page 18: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Analysis of Angioimmunoblastic T-cell lymphoma of the IPTCLP

•  243 AITL patients, Validation GELA cohort •  Standard IPI evaluated •  Alternative Prognostic Index for AITL (PIAI)

•  Age > 60 •  PS > 2 •  ENS > 1 •  B-symptoms present •  Platelet count < 150K

Federico, et al: JCO 31: 240-246, 2013

Page 19: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Overall survival (OS) for patients with angioimmunoblastic T-cell lymphoma (AITL) using the (A) International Prognostic Index, (B) Prognostic Index for Peripheral T-Cell Lymphoma,

Unspecified (PIT), and (C) Prognostic Index for AITL (PIAI); (D) OS for GELA...

Massimo Federico et al. JCO 2013;31:240-246

©2013 by American Society of Clinical Oncology

Page 20: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Survival of Relapsing PTCL

Mak V, et al. J Clin Oncol. 2013;31(16):1970-1976.

153 Relapsed patients 89 treated with chemotherapy ;

no HSCT 52% PTCL NOS Median time to PD: 6.7 months Better outcome with good PS

NOS, not otherwise specified; PD, progressive disease; PS, performance status; PTCL, peripheral T-cell lymphoma

Page 21: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Mak V, et al. J Clin Oncol. 2013;31(16):1970-1976

Page 22: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

German Prospective Trial of ASCT in First Remission

•  PIT group 1: 0 risk factors •  PIT group 2: 1 risk factor •  PIT group 3: 2 risk factors •  PIT group 4: 3-4 risk factors

•  N = 83 untreated patients •  CHOP x 4-6 •  If ≥ PR, dexaBEAM or ESHAP •  dexaBEAM or ESHAP ± TBI,

ASCT •  Median follow-up: 33 mos

Reimer P, et al. J Clin Oncol. 2009;27:106-113.

Nontransplanted patients did poorly

Poor-risk patients did poorly Prop

ortio

n A

chie

ving

OS

1.0

0.8

0.6

0.4

0.2

0 0 12 24 36 48 60

Mos

P < .001

Transplanted (n = 55)

Nontransplanted (n = 28)

Prop

ortio

n A

chie

ving

OS 1.0

0.8

0.6

0.4

0.2

0 0 12 24 36 48 60

Mos

P = .0414

PIT group 2 (n = 34)

PIT group 4 (n = 3) PIT group 3

(n = 21)

PIT group 1 (n = 25)

Page 23: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Molecular Prognostic Indices

•  PTCL- NOS: many different entities • AITL – model using

– P53 upregulation signal – Cytotoxic phenotype – Monocytic/dendritic signature – B-cell signature

Page 24: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Refinement of molecular diagnostic signatures for PTCL subgroups

Relative Level of Expression (x median value)

§  Unique molecular signatures were identified for major PTCL entities

Relative Level of Expression (x median value)

AITL ALK- NK ALK+ ALCL

γδT ATTL

ENKTL PTCL-NOS

Blood. 2014 May 8;123(19):2915-23. Lymphoma and Leukemia Molecular Profiling Project (LLMPP) initiative

Page 25: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Blood 2010;115:1026-1036

Gene expression-based molecular predictors of the major subgroups of PTCL

§  More than half of the PTCL-NOS cases were not molecularly classified

International peripheral T-cell lymphoma Project

Page 26: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

-of 152 PTCL-NOS cases, a subset of cases were classified into i.  AITL [14%] ii. ALK(-)ALCL [11%] iii. ATLL [03%] iv. γδ- PTCL [09%]

- Of 117 AITL cases 26 cases (22%) changed to PTCL-NOS.

Evaluation of pathological vs molecular diagnosis

Blood. 2014 May 8;123(19):2915-23.

Page 27: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Signature Cluster Effect of high expression

Training p-value

Validation p-value

p53 upregulated signature Poor prognosis 0.001 0.014

Cytotoxic signature Poor prognosis 0.005 0.046

Monocytic/dendritic signature Poor prognosis 0.011 0.010

B- cell signature

Good prognosis 0.002 0.017

Quartile

p=0.004

Validation set

Survival prediction on AITL: role of tumor microenvironment

§  Tumor microenvironment significantly influences the prognosis in AITL §  Role of macrophages (M1) vs (M2) and dendritic cells are being investigated

1.0

0.8

0.

6

0.4

0.2

0.0

Training set

P<0.001

Page 28: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Dendrogram for clustering PTCL-NOS cases using centered correlation and complete linkage

CT-PTCL

Cor

rela

tion

Other PTCL-U Other PTCL-U

(A) Hierarchal clustering (C) GSEA analysis

IFNγ responsive genes CD8+ T-cell gene signature P<0.01 P<0.005

(E) Granzyme B expression by immunohistochemistry in CT-PTCL

H & E Granzyme B

Pro

porti

on

Years Years

(D) Survival of the CT-PTCL group

CT-PTCL PTCL-NOS

p=0.05

OS

Pro

porti

on

CT-PTCL PTCL-NOS

p=0.06

EFS

Hours after stimulation

(B) Expression of the CT-PTCL signature in normal CD8+ T-cells stimulated with anti-CD3, anti-CD28 and IL12 for various time intervals (hours)

CD8+ T-cell

0 2 8 24 48

Iden%fica%on  of  cytotoxic  (αβ)  PTCL    group  from  PTCL-­‐NOS  

Blood 2010;115:1026-1036 International peripheral T-cell lymphoma Project

Page 29: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Prognostic gene signatures in AITL

B-cell associated genes and genes inhibitory to myeloid function

Immunosuppressive genes including T-cell activation inhibitor

Good Bad

Iqbal Blood 2010

Long term survivors with AILT do occur – further study needed to identify these patients - ?alternate therapy

Page 30: Prognostic Factors for PTCL - Organizzazione congressi 27, 2015/01. T-cell world/3... · Prognostic Factors for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center

Prognostic Factors for PTCL

• Clinical factors – still important. IPI, PIT, individual histologic models work for low risk groups best

• Biologic factors – pathways, molecular profiling may be more helpful in the future for treatment choices